Charles River Laboratories has agreed to acquire Frontage’s bioanalysis and drug-metabolism testing businesses in Exton, Pennsylvania, for approximately $470 million in cash, plus up to $75 million tied to future performance. The proposed acquisition, announced November 9, would expand Charles River’s work supporting clinical drug development.
The deal is not a purchase of all Frontage for Charles River to keep. Charles River is joining Tigermed and Frontage chairman Dr. Song Li in a consortium to take Hong Kong-listed Frontage private, then divide its businesses. Charles River would retain the Exton bioanalysis and DMPK operations; Tigermed and Li, or his affiliates, would receive the remaining businesses.
Closing is expected in the first half of 2027, subject to regulatory, shareholder and court approvals and other conditions. The company’s announcement describes definitive agreements, not a completed takeover or transfer of the laboratories.
The Exton operations cover two sites with approximately 150,000 square feet and about 340 employees, including a CLIA-certified central laboratory. Their services include bioanalysis, biomarkers and DMPK testing for large- and small-molecule drugs, primarily in clinical development programmes.
DMPK stands for drug metabolism and pharmacokinetics. In plain terms, it examines what the body does to a drug, including how it processes the medicine and how drug levels change over time. Bioanalysis measures drugs and related substances in biological samples. These services supply information researchers need as medicines move through development.
The commercial rationale is to extend Charles River’s testing relationships further into clinical development. About 15% of its current bioanalysis revenue comes from clinical-phase testing, whereas most of Frontage’s bioanalysis revenue in 2025 came from clinical development, according to Charles River. Adding the Exton operations would give it more capacity on that side of the business.
The operations to be acquired represented approximately 40% of Frontage’s total 2025 revenue of $256.7 million. That total belongs to Frontage as a whole, not just the businesses Charles River would retain. The release does not disclose a separate profit figure for the Exton operations or specific customer contracts being transferred.
Charles River expects the transaction to be neutral to non-GAAP earnings per share in 2027 and to add to that measure afterward. That is a company forecast on an adjusted basis, excluding acquisition-related items such as amortization, advisory fees and certain integration costs. It is not a promise that reported GAAP earnings will be unaffected in 2027.
The company expects to fund the acquisition and associated fees through its credit facility and available cash. The initial price is subject to customary closing adjustments, while the additional payments depend on future performance. The announcement does not set out the detailed performance targets for earning the full $75 million.
The legal structure adds steps beyond a direct asset purchase. The consortium’s vehicle would privatize Frontage through a court-sanctioned scheme of arrangement, followed by a withdrawal of its Hong Kong listing and separation into subsidiaries. Approvals include Frontage shareholders, required Tigermed resolutions and sanction by the Grand Court of the Cayman Islands.
Execution remains the central uncertainty: the approvals must be obtained, the businesses separated and the acquired operations integrated. Charles River’s caution identifies possible delays, higher separation costs, missing third-party consents and the loss of clients or key staff as risks. Until closing, the Exton expansion is an agreed transaction with conditions still to be met, rather than capacity already under Charles River’s ownership.
JBizNews Desk | Exton, Pennsylvania, United States
© JBizNews.com. All rights reserved. Unauthorized reproduction or redistribution is strictly prohibited.
